search
Back to results

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Primary Purpose

Thrombotic Microangiopathy

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Ravulizumab
Placebo
Best supportive care
Sponsored by
Alexion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thrombotic Microangiopathy focused on measuring Thrombotic Microangiopathy (TMA) Ultomiris, Ravulizumab, Hematopoietic Stem Cell Transplant (HSCT) Transplant-associated TMA, HSCT-TMA

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 12 years of age or older at time of consent/assent.
  2. Received HSCT within the past 12 months
  3. Diagnosis of TMA that persists for at least 72 hours despite initial management
  4. A TMA diagnosis based on meeting the select criteria during the Screening Period and/or <=14 days prior to the Screening Period.
  5. Body weight ≥ 30 kilograms at Screening.
  6. Female participants of childbearing potential and male participants with female partners of childbearing potential must use highly effective contraception.
  7. Participants must be vaccinated against meningococcal infections if clinically feasible. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis.
  8. Participants or their legally authorized representative must be capable of giving signed informed consent or assent

Exclusion Criteria:

  1. Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency
  2. Shiga toxin producing Escherichia coli infection
  3. Positive direct Coombs test.
  4. Clinical diagnosis of disseminated intravascular coagulation (DIC).
  5. Known bone marrow/graft failure.
  6. Diagnosis of veno-occlusive disease.
  7. Human immunodeficiency virus (HIV) infection.
  8. Unresolved meningococcal disease.
  9. Presence of sepsis requiring vasopressor support.
  10. Pregnancy or breastfeeding.
  11. Previously or currently treated with a complement inhibitor.
  12. Respiratory failure requiring mechanical ventilation.
  13. Acute and/or chronic heart failure.
  14. Participation in an interventional treatment study of any therapy for TMA.

Sites / Locations

  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial Site
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • ClinicalTrial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial ManagerRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Study SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial Site
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Study SiteRecruiting
  • Clinical Study SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Study SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting
  • Clinical Trial SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ravulizumab

Placebo

Arm Description

In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC). In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC).

In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.

Outcomes

Primary Outcome Measures

TMA Response

Secondary Outcome Measures

Time To TMA Response
Proportion of Participants with a Loss of TMA Response
Change from Baseline in eGFR
TMA Relapse
Overall Survival
Non-relapse Mortality
Platelet Response
Concentration (mm^3) of platelets compared to baseline without transfusion support prior to the 7 days.
Hematologic Response
Hematologic Response as assessed by blood tests to measure lactate dehydrogenase (LDH) and platelet count. (1) If baseline platelet count ≤ 50000/mm3, the following criteria must be met: - Absolute platelet count > 50,000/mm3 without platelet transfusion support during the prior 7 days [or] If baseline platelet count > 50,000/mm3, the following criteria must be met: - ≥ 50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days 2) Normalization of LDH and absence of schistocytes

Full Information

First Posted
August 17, 2020
Last Updated
April 26, 2023
Sponsor
Alexion
search

1. Study Identification

Unique Protocol Identification Number
NCT04543591
Brief Title
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
Official Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 16, 2020 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alexion

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thrombotic Microangiopathy
Keywords
Thrombotic Microangiopathy (TMA) Ultomiris, Ravulizumab, Hematopoietic Stem Cell Transplant (HSCT) Transplant-associated TMA, HSCT-TMA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
114 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ravulizumab
Arm Type
Experimental
Arm Description
In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC). In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
Intervention Type
Biological
Intervention Name(s)
Ravulizumab
Other Intervention Name(s)
Ultomiris, ALXN1210
Intervention Description
Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Matching placebo
Intervention Type
Other
Intervention Name(s)
Best supportive care
Intervention Description
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Primary Outcome Measure Information:
Title
TMA Response
Time Frame
26 weeks (treatment period)
Secondary Outcome Measure Information:
Title
Time To TMA Response
Time Frame
26 weeks (treatment period)
Title
Proportion of Participants with a Loss of TMA Response
Time Frame
26 weeks (treatment period)
Title
Change from Baseline in eGFR
Time Frame
26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
Title
TMA Relapse
Time Frame
During the Follow-up Period (183-365 Days after start of study medication)
Title
Overall Survival
Time Frame
26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
Title
Non-relapse Mortality
Time Frame
26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)
Title
Platelet Response
Description
Concentration (mm^3) of platelets compared to baseline without transfusion support prior to the 7 days.
Time Frame
26 weeks (treatment period)
Title
Hematologic Response
Description
Hematologic Response as assessed by blood tests to measure lactate dehydrogenase (LDH) and platelet count. (1) If baseline platelet count ≤ 50000/mm3, the following criteria must be met: - Absolute platelet count > 50,000/mm3 without platelet transfusion support during the prior 7 days [or] If baseline platelet count > 50,000/mm3, the following criteria must be met: - ≥ 50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days 2) Normalization of LDH and absence of schistocytes
Time Frame
26 weeks (treatment period)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 12 years of age or older at time of consent/assent. Received HSCT within the past 12 months Diagnosis of TMA that persists for at least 72 hours despite initial management A TMA diagnosis based on meeting the select criteria during the Screening Period and/or <=14 days prior to the Screening Period. Body weight ≥ 30 kilograms at Screening. Female participants of childbearing potential and male participants with female partners of childbearing potential must use highly effective contraception. Participants must be vaccinated against meningococcal infections if clinically feasible. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis. Participants or their legally authorized representative must be capable of giving signed informed consent or assent Exclusion Criteria: Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency Shiga toxin producing Escherichia coli infection Positive direct Coombs test. Clinical diagnosis of disseminated intravascular coagulation (DIC). Known bone marrow/graft failure. Diagnosis of veno-occlusive disease. Human immunodeficiency virus (HIV) infection. Unresolved meningococcal disease. Presence of sepsis requiring vasopressor support. Pregnancy or breastfeeding. Previously or currently treated with a complement inhibitor. Respiratory failure requiring mechanical ventilation. Acute and/or chronic heart failure. Participation in an interventional treatment study of any therapy for TMA.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexion Pharmaceuticals Inc.
Phone
855-752-2356
Email
clinicaltrials@alexion.com
Facility Information:
Facility Name
Clinical Trial Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Clinical Trial Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46237
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Grosse Pointe Farms
State/Province
Michigan
ZIP/Postal Code
48236
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Murdoch
Country
Australia
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Parkville
Country
Australia
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Westmead
Country
Australia
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Brugge
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Bruxelles
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Chênée
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Leuven
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Yvoir
Country
Belgium
Individual Site Status
Recruiting
Facility Name
ClinicalTrial Site
City
Florianopolis
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Montreal
Country
Canada
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Toronto
Country
Canada
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Angers
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
La Tronche
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Manager
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Nice
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Pierre-Bénite
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Toulouse
Country
France
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Chemnitz
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Halle
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Hamburg-Eppendorf
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Mainz
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Athens
Country
Greece
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Patra
Country
Greece
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Thessaloniki
Country
Greece
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Haifa
Country
Israel
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Ramat Gan
Country
Israel
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Ancona
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Avellino
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Cuneo
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Firenze
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Study Site
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Naples
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Rome
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Salerno
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
San Giovanni Rotondo
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Clinical Trial Site
City
Torino
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Udine
Country
Italy
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Akita
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Anjo
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Study Site
City
Chiba
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Study Site
City
Fukushima
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Isehara
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Study Site
City
Kanazawa
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Kobe
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Kumamoto
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Kurashiki
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Nagaizumi-chō
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Okayama
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Osakasayama
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Osaka
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Sapporo
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Suita
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Tokyo
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Tsukuba
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Wakayama
Country
Japan
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Goyang
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Suwon
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Groningen
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Maastricht
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Gdansk
Country
Poland
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Granada
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Majadahonda
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Málaga
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Oviedo
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Palma De Mallorca
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Pamplona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Salamanca
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
San Sebastián
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Sevilla
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Valencia
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Huddinge
Country
Sweden
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Lund
Country
Sweden
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Glasgow
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Leicester
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Clinical Trial Site
City
Nottingham
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

We'll reach out to this number within 24 hrs